Preclinical investigation of novel super-selective mTOR inhibitors in colorectal cancer

Dr Asier Unciti-Broceta, Prof Owen Sansom, Prof Margaret Frame


Unciti-Broceta Lab
Sansom Lab
Frame Lab
Duration: 4 years from September 2022
Closing Date: 27th May 2022

About us

Applications are invited from outstanding candidates to join a Cancer Research UK funded PhD programme at the Edinburgh Cancer Research Centre. These are funded by the Cancer Research UK Scotland Centre, a joint initiative between Edinburgh and Glasgow which brings together cancer scientists and clinicians from across the Universities of Edinburgh and Glasgow, delivering outstanding cancer research and improved patient care. The Cancer Research UK PhD programme is integrated into the research activities of the Centre with over 80 principal investigators contributing to this cross-disciplinary programme spanning from fundamental science to translational research. Research projects benefit from state-of-the art facilities for genomics, mass spectrometry, advanced microscopy, single cell technologies, and from advanced computational and informatics capabilities.

Project Description

The development of potent and selective small molecules that mediate dose-dependent inhibition of a protein in its natural environment is essential to elucidate the role of such nominated target in normal and pathological settings [1]. This is especially true in cancers where multiple aetiological factors are involved in tumourigenesis and cancer progression. The mechanistic target of rapamycin (mTOR) is a serine/threonine protein kinase that operates as the catalytic subunit of two multiprotein complexes, mTORC1 and mTORC2. These complexes act as sensors that integrate multiple extracellular and intracellular signals to coordinate cell metabolism, proliferation, survival and migration. Increased mTOR kinase activity is found in approximately half of all human malignancies including colorectal cancer, via genetic dysregulation of different upstream regulators of mTORC1 and / or mTORC2 signalling. Rapalogs (rapamycin, everolimus) are a family of clinically approved macrolide drugs that stops mTORC1 signalling through an allosteric interaction that does not occur in the mTORC2 complex, thus inhibiting mTORC1 activity with superb selectivity [2]. Sansom's lab demonstrated that mTORC1 is an essential downstream effector of Wnt-signalling in the intestine and showed that treatment of APC-deficient colorectal adenomas with rapalogs causes tumour cells to undergo growth arrest and differentiation [3]. However, following further mutation in KRAS, rapalogs are no longer sufficient to control tumour growth [4], highlighting the need for broader inhibition of mTOR. Furthermore, other studies have also shown that mTORC2 is an important driver of cancer cell proliferation and survival in other malignancies [5]. By the simultaneous inhibition of both complexes, small molecules that block the kinase domain of mTOR are optimal to challenge rapalogs and establish whether one or both complexes need to be blocked to achieve maximal anticancer effect in different cancer types and subtypes. The problem is that current mTOR inhibitors also inhibit other related kinases (e.g. PI3K), making impossible to dissect the differential effects of blocking one or both complexes in a pharmacological manner. Finally yet importantly, although mTOR inhibitors display superior anticancer activities than rapalogs against most cancers [5], their off-target activity results in dose-limiting toxicities that have so far precluded their regulatory approval.

Unciti-Broceta and Frame (Edinburgh) have discovered a novel class of super-potent mTOR inhibitors with unprecedented selectivity for its target when compared with the rest of the kinome (see Figure) and high antiproliferative potency against cancer cells, but not normal cells [Unpublished results, patent in preparation]. In collaboration with Sansom (Glasgow), we propose to use these best-in-class dual mTORC1/2 inhibitors and mTORC1-selective rapalogs to elucidate the role of mTOR Complex 1 and 2 in genetically engineered mouse models (GEMMs) of colorectal cancer (CRC) in cell culture, tumour organoids and in vivo. Results from the screens will inform the medicinal chemistry lead optimisation campaign and / or nominate a clinical candidate. By using a wealth of medchem methods, cell assays, imaging and molecular biology techniques, and animal models, this truly multidisciplinary project will provide the student with a unique set of skills and ―at the same time― will accelerate the preclinical development and translation of a promising class of inhibitors with high therapeutic potential.

Application Procedure

Up to 3 studentships are available to start in September 2022 for outstanding applicants with a stipend of £19,000 p/a. These are funded by the CRUK Scotland Centre, a joint initiative between Edinburgh and Glasgow. Successful students will be registered for their degree in either Glasgow or Edinburgh, depending on the project they apply for.

We are looking for students with a very good degree in a Life Sciences subject and an aptitude for experimental work, who are also highly committed to pursuing a PhD and a career in cancer research. You should hold at least an upper second-class degree in a relevant subject and comply with English language requirements.

All applications will be administered centrally via the University of Edinburgh, please apply on the link below- this includes Glasgow-based projects with Glasgow-based supervisors:

Closing date: 27 May 2022

Interviews are expected to be held week beginning 27 June.

Applications are open to all individuals irrespective of nationality or country of residence.



Research Mahnoor 290x200

Read more about the Research Groups working at the Beatson Institute.



Seminars 2021

Find out more about our seminars including our Distinguished Seminar Programme.